Nasonex spray nasal (suspension)

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

mometasone (mometasone furoate)

Доступна с:

Schering-Plough Labo N.V.

код АТС:

R01AD09

ИНН (Международная Имя):

mometasone (mometasone furoate)

дозировка:

50mcg/dose

Фармацевтическая форма:

spray nasal (suspension)

Штук в упаковке:

18g (140 dose) plastic bottle with spray pump 18g (140 dose)

Тип рецепта:

Prescription

Статус Авторизация:

Registered

Дата Авторизация:

2020-05-05

Характеристики продукта

2
SUMMARY OF PRODUCT CHARACTERISTICS
10
1.
NAME OF THE MEDICINAL PRODUCT
NASONEX
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_composition: _
one spray dose contains mometasone furoate monohydrate equivalent to
50 mcg
mometasone furoate (anhydrous).
_excipients: _
dispersible cellulose, glycerol, sodium citrate dehydrate, citric
acid, polysorbate 80,
benzalkonium chloride, purified water.
3.
PHARMACEUTICAL FORM
A metered-dose nasal spray.
_basic physical and chemical properties_
: white to off-white powder opaque suspension
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
•
Treatment of seasonal allergic or perennial rhinitis in adults and
children 2 years of age and
older.
•
In patients 12 years of age and older who have a history of moderate
to severe symptoms of
seasonal allergic rhinitis, prophylactic treatment may be initiated up
to 2-4 weeks prior to the
anticipated start of the pollen season.
•
Treatment of symptoms associated with acute rhinosinusitis in patients
12 years of age and
older without signs of severe bacterial infection.
•
Treatment of nasal polyps and associated symptoms including congestion
and loss of smell
in adult patients 18 years of age and older.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Treatment of seasonal or perennial allergic rhinitis: _
for adults (including geriatric patients) and
children 12 years of age and older the recommended preventive and
therapeutic dose is 2
actuations (50 micrograms/actuation) in each nostril once daily (total
dose 200 micrograms).
Once symptoms are controlled, dose reduction to one actuation in each
nostril (total dose 100
micrograms) may be effective for maintenance.
If symptoms are inadequately controlled at the recommended therapeutic
dose, the daily dose
may be increased to a maximum daily dose: of 4 actuations in each
nostril once daily (total
dose 400 micrograms). Dose reduction is recommended following control
of symptoms.
This medicinal product demonstrates a clinically significant onset of
action within 12 hours
after the first dos